Table 4.
Stratified log-rank test for the duration of primary patency in the FAS
| Stratum | AMG0102 group, n |
PTA group, n | Score | Square of score | Variance of score | χ2 value | DF | HRa | 95% CIa | P |
|---|---|---|---|---|---|---|---|---|---|---|
| Without diabetes complications | 58 | 28 | −0.801 | 0.642 | 9.445 | 0.068 | 1 | 0.919 | 0.486–1.738 | 0.794 |
| With diabetes complications | 53 | 29 | −4.358 | 18.990 | 10.704 | 1.774 | 1 | 0.666 | 0.366–1.212 | 0.183 |
| Total χ2 value | — | — | — | — | — | 1.842 | — | — | — | — |
| Stratified log-rank test | 111 | 57 | −5.159 | 26.613 | 20.149 | 1.321 | 1 | 0.774 | 0.500–1.198 | 0.250 |
| The test of stratification consistency for treatment efficacy | — | — | — | — | — | 0.521 | 1 | — | — | 0.470 |
CI, confidence interval; DF, degrees of freedom; FAS, full analysis set; HR, hazard ratios; PTA, percutaneous transluminal angioplasty.
a
Values based on the stratified log-rank test score. Hazard ratio was calculated as AMG0102 group hazard/PTA group hazard.